http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ha Ra Gu,Su Cheol Park,Su Jin Choi,Jae Cheol Lee,You Cheoul Kim,Chul Ju Han,Ki Young Yang,김연주,Geum Youb Noh,So Hyeon No,Jae-Hoon Jeong 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.1
Background/Aims: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. Methods: Several different human HCC cell lines were used to test the growth-inhibiting effects and cell toxicity of silibinin both alone and in combination with either gefitinib or sorafenib. The cell viability and growth inhibition were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, trypan blue staining, and a colony-forming assay. Furthermore, changes in epidermal growth factor receptor (EGFR)-related signals were evaluated by Western blot analysis. Results: Gefitinib, sorafenib, and silibinin individually exhibited dose-dependent antiproliferative effects on HCC cells. Combined treatment with silibinin enhanced the gefitinib-induced growth-inhibiting effects in some HCC cell lines. The combination effect of gefitinib and silibinin was synergistic in the SNU761 cell line, but was only additive in the Huh-BAT cell line. The combination effect may be attributable to inhibition of EGFR-dependent Akt signaling. Enhanced growth-inhibiting effects were also observed in HCC cells treated with a combination of sorafenib and silibinin. Conclusions: Combined treatment with silibinin enhanced the growth-inhibiting effects of both gefitinib and sorafenib. Therefore, the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future. (Clin Mol Hepatol 2015;21:49-59)
( Ha Ra Gu ),( Su Cheol Park ),( Su Jin Choi ),( Jae Cheol Lee ),( You Cheoul Kim ),( Chul Ju Han ),( Jin Kim ),( Ki Young Yang ),( Yeon Joo Kim ),( Geum Youb Noh ),( So Hyeon No ),( Jae Hoon Jeong ) 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.1
Background/Aims: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. Methods: Several different human HCC cell lines were used to test the growth-inhibiting effects and cell toxicity of silibinin both alone and in combination with either gefitinib or sorafenib. The cell viability and growth inhibition were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, trypan blue staining, and a colony-forming assay. Furthermore, changes in epidermal growth factor receptor (EGFR)-related signals were evaluated by Western blot analysis. Results: Gefitinib, sorafenib, and silibinin individually exhibited dose-dependent antiproliferative effects on HCC cells. Combined treatment with silibinin enhanced the gefitinib-induced growth-inhibiting effects in some HCC cell lines. The combination effect of gefitinib and silibinin was synergistic in the SNU761 cell line, but was only additive in the Huh-BAT cell line. The combination effect may be attributable to inhibition of EGFR-dependent Akt signaling. Enhanced growth-inhibiting effects were also observed in HCC cells treated with a combination of sorafenib and silibinin. Conclusions: Combined treatment with silibinin enhanced the growth-inhibiting effects of both gefitinib and sorafenib. Therefore, the combination of silibinin with either sorafenib or gefitinib could be a useful treatment approach for HCC in the future. (Clin Mol Hepatol 2015;21:49-59)
Eun-Ha Kim,Soo-Yun Park,So-Ra Jin,Sang-Gu Lee,Hyoun-Min Park,Oh-Suk Yu,Yun-Young Kang,Min-Ho Lee,Tae-Hun Ryu,Young-Soo Chung,Seon-Woo Oh 한국식품영양과학회 2021 한국식품영양과학회 학술대회발표집 Vol.2021 No.10
Untargeted metabolomics approaches offer advantages to characterize substantial equivalence among transgenic and nontransgenic crops. To investigate the substantial equivalence of PfFAD3-1 transgenic soybean lines expressing omega-3 fatty acid desaturase 3-1 gene (FAD3-1) of Physaria, profiles of hydrophillic metabolites were obtained using a GC-TOFMS in the three PfFAD3-1 lines and nontransgenic conventional varieties cultivated at Jeonju and Gunwi in 2020. In total, 40 metabolites were identified including organic acids, amino acid, and sugars. The level of ferulic acid was significantly higher in each PfFAD3-1 line compared to its direct counterpart, and the ferulic acid means of PfFAD3-1 lines were not presented in the range of reference lines. The principal components analysis showed a clear separation in the metabolite profiling between cultivation locations, indicating that the metabolic compositions in Soybean seeds could be more altered by environment rather than by genotype alone. It was suggested to include more reference varieties and cultivation years to assess the altered change in the levels of ferulic acid in PfFAD3-1 lines in relation to natural variation.
이상구(Sang-Gu Lee),오선우(Seon-Woo Oh),박수윤(Soo-Yun Park),박현민(Hyoun-Min Park),김은하(Eun-Ha Kim),진소라(So-Ra Jin),류태훈(Tae-Hun Ryu) 한국식물생명공학회 2021 JOURNAL OF PLANT BIOTECHNOLOGY Vol.48 No.4
To ensure the safety of developing or importing genetically modified organisms (GMOs), Korea has enacted the “LMO Act.” Accordingly, the safety of using GMOs as food or feed is evaluated in accordance with the concept of “substantial equivalence” proposed by OECD. The allergenicity of GMOs is assessed as a part of their safety evaluation. The methods of allergenicity assessment have been discussed by various international organizations, such as the OECD, FAO, and WHO. The main methods used for the allergenicity assessment of proteins newly expressed in GMOs include assessment of the physicochemical stability of these proteins, evaluation of their amino acid homology with existing allergenic proteins, and serum screening. In this study, we describe guidelines and related studies for the allergenicity assessment of GM crops.
Phenylhydrazine으로 유도한 용혈성 빈혈 흰쥐에 대한 녹용 추출물의 조혈 효과
이미라(Mi-Ra Lee),김현호(Hyun-Ho Kim),조현호(Hyun-Ho Jo),강효진(Hyo-Jin Kang),고리주안(LiJuan Gu),이선영(Sun-Young Ly),이청하(Chung-Ha Lee),김승미(Seung-Mi Kim),양선아(Sun-Ah Yang),모은경(Eun-Kyung Mo),성창근(Chang-Keun Sung) 한국식품영양과학회 2009 한국식품영양과학회지 Vol.38 No.12
본 연구는 부위별 녹용 추출물이 PHZ 투여로 용혈성 빈혈을 유도한 흰쥐의 조혈작용에 대한 효과를 검증하고자 하였다. 4주령의 암컷 Sprague-Dawley 흰쥐에 PHZ 10 ㎎/㎏을 4일간 미정맥 주사하여 용혈성 빈혈을 유발한 후 각 부위별 녹용 추출물 200 ㎎/㎏을 일주일간 경구투여 하였다. 용혈성 빈혈 유발군인 PHZ군은 hemoglobin, hematocrit치, 적혈구수가 대조군에 비해 유의적으로 감소하였고, 망상적혈구수는 유의적으로 증가하였다. 반면, 녹용 추출물 군에서는 hemoglobin, hematocrit치, 적혈구수가 PHZ 투여군보다 증가하였다. 특히 분골, 상대, 중대 추출물 투여 시 유의성 있게 증가하였다. 상대 추출물 투여군에서는 망상적혈구수 증가가 유의적으로 억제되었다. PHZ 투여로 증가된 혈청 EPO 함량은 녹용 추출물 투여군에서 모두 정상적으로 회복되었다. Hemoglobin 합성에 관여하는 δ-ALAD 활성은 녹용 추출물 투여군에서 활성이 증가되는 결과를 보여주었다. 따라서 녹용 추출물은 PHZ으로 유도한 용혈성 빈혈에 대한 바람직한 조혈효과가 있는 기능성 물질로 사료된다. This study was to investigate the protection of the extracts from four parts of deer antler in an anemia model induced by intravenous injection of phenylhydrazine·HCl (PHZ) at 10 mg/kg for 4 days. After PHZ injection, female Sprague-Dawley rats were administrated partial deer antler extract (200 ㎎/㎏/day, p.o.) daily for 1 week. Results showed that sever hemolysis was induced by PHZ. For antler extract-treated groups, the concentration of hemoglobin, hematocrit and red blood cells number increased much more significantly than PHZ-treated group. Upper antler extract-treated group was more remarkable than other parts in suppressing the increase of reticulocyte in whole blood. Moreover, antler extract administration significantly improved serum erythropoietin concentration. The activity of δ-aminolevulinic acid dehydrates (ALAD) in liver homogenate was increased in antler extract-treated groups, especially middle and base extract-treated groups showed statistical significance. These results could be concluded that the deer antler extract improved anemia induced by PHZ injection through improving hematological values, serum EPO value, ALAD enzyme activity.